Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Major Depressive Disorder
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Total Rewards
    • Recruiting Agencies
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Major Depressive Disorder
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Total Rewards
    • Recruiting Agencies
  • Pipeline
  • Dementia-Related Psychosis
  • Major Depressive Disorder
  • Rett Syndrome
  • Schizophrenia – Negative Symptoms

Our Pipeline

Our pipeline includes innovative product candidates in CNS areas:

Pipeline Chart 11-27-19Pipeline Chart 11-27-19

  • Print page
  • Share
  • Privacy
  • Terms
  • Email

© 2019 ACADIA Pharmaceuticals Inc. ACADIA and NUPLAZID are registered trademarks of ACADIA Pharmaceuticals Inc. All rights reserved.